Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection

Gregory J. Dore, David L Thomas

Research output: Contribution to journalArticle

Abstract

Injection drug use is the major mode of hepatitis C virus (HCV) transmission in developed countries. Despite this, relatively few current and recovering injection drug users (IDUs) have received HCV treatment. Studies among individuals with a recent history of injection drug use or those receiving drug dependency treatment have provided evidence that these groups can be successfully treated for chronic HCV infection. These studies have provided the impetus to change guidelines for treatment of current and recovering IDUs, with a move toward individualized HCV treatment assessment and the removal of defined periods of illicit drug use abstinence. Strategies to improve access to HCV treatment for current and recovering IDUs include drug dependency treatment education and training for hepatologists and other HCV treatment physicians, HCV treatment education and training for addiction medicine physicians, development of multidisciplinary clinics, and peer-based eduction and support for individuals considering and receiving HCV treatment.

Original languageEnglish (US)
Pages (from-to)18-32
Number of pages15
JournalSeminars in Liver Disease
Volume25
Issue number1
DOIs
StatePublished - Feb 2005

Fingerprint

Virus Diseases
Drug Users
Coinfection
Hepacivirus
HIV
Injections
Therapeutics
Pharmaceutical Preparations
Physicians
Education
Street Drugs
Chronic Hepatitis C
Developed Countries
Medicine
Guidelines

Keywords

  • Hepatitis C
  • HIV/HCV coinfection
  • Injection drug users

ASJC Scopus subject areas

  • Hepatology

Cite this

@article{e46b36d32812439485f202d5187c4fa7,
title = "Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection",
abstract = "Injection drug use is the major mode of hepatitis C virus (HCV) transmission in developed countries. Despite this, relatively few current and recovering injection drug users (IDUs) have received HCV treatment. Studies among individuals with a recent history of injection drug use or those receiving drug dependency treatment have provided evidence that these groups can be successfully treated for chronic HCV infection. These studies have provided the impetus to change guidelines for treatment of current and recovering IDUs, with a move toward individualized HCV treatment assessment and the removal of defined periods of illicit drug use abstinence. Strategies to improve access to HCV treatment for current and recovering IDUs include drug dependency treatment education and training for hepatologists and other HCV treatment physicians, HCV treatment education and training for addiction medicine physicians, development of multidisciplinary clinics, and peer-based eduction and support for individuals considering and receiving HCV treatment.",
keywords = "Hepatitis C, HIV/HCV coinfection, Injection drug users",
author = "Dore, {Gregory J.} and Thomas, {David L}",
year = "2005",
month = "2",
doi = "10.1055/s-2005-864779",
language = "English (US)",
volume = "25",
pages = "18--32",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection

AU - Dore, Gregory J.

AU - Thomas, David L

PY - 2005/2

Y1 - 2005/2

N2 - Injection drug use is the major mode of hepatitis C virus (HCV) transmission in developed countries. Despite this, relatively few current and recovering injection drug users (IDUs) have received HCV treatment. Studies among individuals with a recent history of injection drug use or those receiving drug dependency treatment have provided evidence that these groups can be successfully treated for chronic HCV infection. These studies have provided the impetus to change guidelines for treatment of current and recovering IDUs, with a move toward individualized HCV treatment assessment and the removal of defined periods of illicit drug use abstinence. Strategies to improve access to HCV treatment for current and recovering IDUs include drug dependency treatment education and training for hepatologists and other HCV treatment physicians, HCV treatment education and training for addiction medicine physicians, development of multidisciplinary clinics, and peer-based eduction and support for individuals considering and receiving HCV treatment.

AB - Injection drug use is the major mode of hepatitis C virus (HCV) transmission in developed countries. Despite this, relatively few current and recovering injection drug users (IDUs) have received HCV treatment. Studies among individuals with a recent history of injection drug use or those receiving drug dependency treatment have provided evidence that these groups can be successfully treated for chronic HCV infection. These studies have provided the impetus to change guidelines for treatment of current and recovering IDUs, with a move toward individualized HCV treatment assessment and the removal of defined periods of illicit drug use abstinence. Strategies to improve access to HCV treatment for current and recovering IDUs include drug dependency treatment education and training for hepatologists and other HCV treatment physicians, HCV treatment education and training for addiction medicine physicians, development of multidisciplinary clinics, and peer-based eduction and support for individuals considering and receiving HCV treatment.

KW - Hepatitis C

KW - HIV/HCV coinfection

KW - Injection drug users

UR - http://www.scopus.com/inward/record.url?scp=14644391458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644391458&partnerID=8YFLogxK

U2 - 10.1055/s-2005-864779

DO - 10.1055/s-2005-864779

M3 - Article

C2 - 15731995

AN - SCOPUS:14644391458

VL - 25

SP - 18

EP - 32

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 1

ER -